中文
cancer per annum which accounts for approx. 40% of the gastric cancer deaths worldwide. At present, the problem of drug resistance of Helicobacter pylori eradication drugs is becoming more and more serious. The bismuth quadruple regimen recommended in the Sixth National Consensus Report on the Management of Helicobacter Pylori Infection requires individualized treatment and cannot meet the needs of eradication in a wide range of populations. There is an urgent need to develop a first-line treatment regimen that is safe, effective, simple, can effectively overcome drug resistance, and is seamlessly connected with urease breath diagnosis.
Medical Needs
Antimicrobial agents are the cornerstone of modern medicine, saving countless lives and making many common surgeries possible. However, the problem of antimicrobial resistance is becoming more and more serious and has become a major challenge to the prevention and treatment of bacterial infections. At present, some important pathogenic bacteria have developed resistance to almost all existing antibacterial drugs, rendering the clinical treatment extremely difficult. Should this situation not be effectively under control, humans are likely to enter the "post-antibiotic era". Meanwhile, along with the progress of medical science, new types of infections e.g. biofilm infection associated with implanted medical devices have been emerging, which are lack of effective therapies. The development of high-throughput gene sequencing technology and microbiomics has offered better understanding and new mechanism for the treatment of diseases associated with bacterial metabolism and microbiome, such as hepatic encephalopathy, diarrhea-predominant irritable bowel syndrome, inflammatory bowel disease and NASH. TenNor focuses on the research and development of new drugs in the field of bacterial infections and metabolic related diseases. TenNor has developed a highly differentiated innovation pipeline with global patent protection, aiming at the “first-in-class” or “best-in-class” new drug therapies to address the unmet needs in the related therapeutic fields.
- H. pylori InfectionH. pylori is a critical pathogen causing chronic gastritis, peptic ulcer and gastric cancer. The infection rate in Chinese adult population is up to 50%, causing more than 340,000 new cases of gastric...
Medical Device Associated Bacterial Biofilm InfectionWith the aging of population and the progress of medical science and technology, the use of implantable medical devices, such as artificial joints, central venous catheters, artificial heart valves, cardiac pacemakers, artificial hearts, etc., ...is becoming more and more common, and the ensuing infection of implantable medical devices is becoming a rapidly growing unmet clinical need. About 25.6% of medical infections in the United States are associated with implanted medical devices, resulting in 1.7 million infections per year and a $11 billion economic burden. Implanted medical devices provide a harbor for bacteria to colonize the device surface and form biofilms, resulting in poor therapeutic effect of existing antibacterial drugs. Replacement surgery is the main means for the treatment of implanted medical device infection in clinical practice, which is expensive and brings great pain to patients.
- Liver Cirrhosis Hepatic EncephalopathyWorldwide, more than 10 million patients suffer from decompensated stage cirrhosis, resulting in more than 1 million deaths, and more deaths from cirrhosis than from liver cancer. In cirrhotic portal hypertension, hepatocyte dysfunction reduces ...
the detoxification function of toxic substances such as ammonia, so that a large number of toxic substances such as ammonia absorbed into the blood by the intestine pass through the portal vein, bypass the liver and directly flow into the systemic circulation and enter the brain tissue, leading to hepatic encephalopathy. Hepatic encephalopathy develops in 30-45% of patients with cirrhosis, and less than 50% of patients with hepatic encephalopathy survive within one year, which has a serious impact on patients' quality of life. The US FDA has approved only three drugs for the treatment and prevention of hepatic encephalopathy, and the global pipeline for the development of new drug R & D products is weak and there are significant unmet clinical needs.
